Treatment of ear, nose and throat infections with clofoctol.
Fifty-two adult patients affected by infectious otorhinolaryngological diseases were treated rectally with clofoctol, a new chemotherapeutic phenol derivative. The clinical diagnoses included tonsillitis, paranasal sinus infections, nose and nasopharyngeal infections, external ear canal and middle ear infections. Evaluation of the results was based on clinical and bacteriological data; the effectiveness of the drug was also confirmed by statistical reference to a control group consisting of 52 adult patients affected by otorhinolaryngological infections treated only with topical agents or not treated at all. In the patients treated with clofoctol, good therapeutic results were obtained in over 90% of cases. Only four patients showed mild adverse reactions. On the whole, results demonstrated that clofoctol is very valuable for the management of most of the infectious diseases common in ENT practice.
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002722:Chlorobenzenes; D002986:Clinical Trials as Topic; D003408:Cresols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002722:Chlorobenzenes; D003408:Cresols; C018874:clofoctol